Recent Updates
Recently added Catalysts
PTN

Palatin Technologies To Participate In The 25th Annual Piper Jaffray Healthcare Conference

Key Takeaway: CRANBURY, N.J., Dec. 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company's chief executive officer, will participate in a "Fireside Chat" at the 25th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on Dece

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~4 mo
High dilution risk
Lead asset
Bremelanotide
Phase 3 · Hypoactive Sexual Desire Disorder

Full Press Release Details

CRANBURY, N.J., Dec. 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company's chief executive officer, will participate in a "Fireside Chat" at the 25th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on December 4, 2013. The conference will be held at the New York Palace hotel in New York City. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through December 10, 2013.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.
Last updated: Dec 2, 2013